News

The Chronic Obstructive Pulmonary Disease Foundation and DevPro Biopharma have established a partnership to develop new therapies for people with chronic obstructive pulmonary disease (COPD) and other lung disorders. The collaborators will work to identify potential therapies and speed their development and possible regulatory approval. The aim is to enable new treatments…

Neurological and psychological disorders that often coexist in patients with chronic obstructive pulmonary disease (COPD) may be grouped into two distinct clusters or patterns, according to a recent study. Investigators noted these clusters and disease patterns may be helpful for physicians caring for these patients in clinical practice, as…

In response to an acute respiratory viral infection, a type of sentinel immune cell — called dendritic cells — trigger a chain of events that can lead to lung diseases that include chronic obstructive pulmonary disease, a study in mice found. The study, “TLR3-Activated Monocyte-Derived Dendritic Cells Trigger Progression…

X-PLO₂R, a portable oxygen concentrator developed by Belluscura and its research partner Separation Design Group, has been cleared for commercialization in the U.S. The Food and Drug Administration (FDA) cleared the company’s premarket notification, or 510(k), and granted marketing authorization to the new device. Premarket notification is a formal…

A Royal Academy of Engineering Research Fellow in the U.K. has been awarded a £500,000 (nearly $700,000) grant to develop a computational model of the lung — a sort of “virtual lung” — that may be a game-changer in the development of new therapies and in the ways of caring…

Patients with chronic obstructive pulmonary disease (COPD) are more likely to develop ventricular arrhythmia, a heart rhythm disorder affecting the heart’s lower chambers or ventricles, than people without the disease, according to a Taiwanese nationwide study. Later analysis of that study also found that people with both COPD and…

Lung function and quality of life remained stable over three years of follow-up among people with chronic obstructive pulmonary disease (COPD) treated with targeted lung denervation (TLD) — a new therapy developed by Nuvaira — according to the results of a clinical trial. That trial, called AIRFLOW-1 (…

Two Montreal-based foundations are joining forces to boost research and care into complex and chronic respiratory disorders, including chronic obstructive pulmonary disease (COPD). The merging of the McGill University Health Centre (MUHC) Foundation and the Montreal Chest Institute (MCI) Foundation comes as the MUHC opens a $10 million…

A new collaboration is seeking to bring quantitative imaging analysis to diagnosis and care of patients with chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and emphysema. The agreement is between Spesana, a healthcare platform focused on molecular diagnostics and in building an accessible database for physicians,…

The U.S. Food and Drug Administration (FDA) has cleared the start of an international pivotal trial to test the RheOx System, Gala Therapeutics’ medical device, in adults with chronic obstructive pulmonary disease (COPD) who have moderate to severe chronic bronchitis. “Chronic bronchitis is a debilitating disease which results…